Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | NT5E | P21589 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18067101 | 1.00 | CYP3A4 (0.55) | CYP3A4CYP2C9NT5EADORA3ADORA1 | |
| SCHEMBL19644781 | 1.00 | CYP3A4 (0.55) | CYP3A4CYP2C9NT5EADORA3ADORA1 | |
| SCHEMBL18067100 | 1.00 | CYP3A4 (0.55) | CYP3A4CYP2C9NT5EADORA3ADORA1 | |
| SCHEMBL21101684 | 1.00 | CYP3A4 (0.55) | CYP3A4CYP2C9NT5EADORA3ADORA1 | |
| SCHEMBL19833071 | 1.00 | CYP3A4 (0.55) | CYP3A4CYP2C9NT5EADORA3ADORA1 | |
| SCHEMBL23790918 | 0.95 | CYP3A4 (0.54) | CYP3A4CYP2C9NT5EADORA3ADORA1 | |
| SCHEMBL18067104 | 0.95 | CYP3A4 (0.54) | CYP3A4CYP2C9NT5EADORA3ADORA1 | |
| SCHEMBL19644709 | 0.95 | CYP3A4 (0.54) | CYP3A4CYP2C9NT5EADORA3ADORA1 | |
| SCHEMBL19644707 | 0.95 | CYP3A4 (0.54) | CYP3A4CYP2C9NT5EADORA3ADORA1 | |
| SCHEMBL19644708 | 0.95 | CYP3A4 (0.54) | CYP3A4CYP2C9NT5EADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238324-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20230364121-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | Atea Pharmaceuticals, Inc. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11738038-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11707480-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20210275563-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2021-09-09 | — | — | US | disclosed |
| US-20210009628-A1 | Beta-D-2'-DEOXY-2'-Alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2021-01-14 | — | — | US | disclosed |
| US-10875885-B2 | β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10874687-B1 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10870672-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2020-12-22 | — | — | US | disclosed |
| US-10815266-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200331956-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200331955-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200308215-A1 | Beta-D-2'-DEOXY-2'-Alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2020-10-01 | — | — | US | disclosed |
| US-20190177356-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2019-06-13 | — | — | US | disclosed |
| US-10239911-B2 | Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10005811-B2 | β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180030082-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. | 2018-02-01 | — | — | US | disclosed |
| US-9828410-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2017-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707480-B2 | Highly active compounds against COVID-19 | PNP, MTAP, ACE2 | CYP3A4 2868/4885CYP2C9 1842/4885NT5E 28/4885 |
| US-20200331955-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | CYP3A4 3614/4885CYP2C9 3851/4885NT5E 62/4885 |
| US-20230364121-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | NSUN2, ACE2, PNP | CYP3A4 344/4885CYP2C9 1644/4885NT5E 131/4885 |
| US-10874687-B1 | Highly active compounds against COVID-19 | PNP, MTAP, ACE2 | CYP3A4 2868/4885CYP2C9 1842/4885NT5E 28/4885 |
| US-10005811-B2 | β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | NSUN2, PNP, NUDT1 | CYP3A4 3492/4885CYP2C9 3976/4885NT5E 45/4885 |
| US-10239911-B2 | Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | NSUN2, NUDT1, PNP | CYP3A4 3575/4885CYP2C9 3835/4885NT5E 57/4885 |
| US-11813278-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | CYP3A4 1696/4885CYP2C9 944/4885NT5E 29/4885 |
| US-20210009628-A1 | Beta-D-2'-DEOXY-2'-Alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | CYP3A4 3614/4885CYP2C9 3851/4885NT5E 62/4885 |
| US-11738038-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | CYP3A4 1696/4885CYP2C9 944/4885NT5E 29/4885 |
| US-20200331956-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | CYP3A4 3614/4885CYP2C9 3851/4885NT5E 62/4885 |
| US-10875885-B2 | β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n6-substituted purine nucleotides for HCV treatment | NSUN2, PNP, NUDT1 | CYP3A4 3228/4885CYP2C9 3652/4885NT5E 49/4885 |
| US-10815266-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | NSUN2, PNP, NUDT1 | CYP3A4 3228/4885CYP2C9 3652/4885NT5E 49/4885 |
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | NUDT1, PNP, ATIC | CYP3A4 1370/4885CYP2C9 906/4885NT5E 72/4885 |
| US-20210275563-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | PNP, MTAP, ACE2 | CYP3A4 2868/4885CYP2C9 1842/4885NT5E 28/4885 |
| US-20200308215-A1 | Beta-D-2'-DEOXY-2'-Alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | CYP3A4 3614/4885CYP2C9 3851/4885NT5E 62/4885 |
| US-20180030082-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | CYP3A4 3731/4885CYP2C9 3994/4885NT5E 52/4885 |
| US-20240238324-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | PNP, MTAP, ACE2 | CYP3A4 2868/4885CYP2C9 1842/4885NT5E 28/4885 |
| US-20190177356-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | NSUN2, NUDT1, DCTD | CYP3A4 3614/4885CYP2C9 3851/4885NT5E 62/4885 |
| US-10870672-B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | NSUN2, PNP, NUDT1 | CYP3A4 3228/4885CYP2C9 3652/4885NT5E 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.